MIESF yields 0.57% · JNJ yields 2.13%● Live data
📍 MIESF pulled ahead of the other in Year 1
Combined, MIESF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MIESF + JNJ for your $10,000?
Mitsui E&S Holdings Co., Ltd. engages in the shipbuilding and engineering businesses worldwide. The company operates through four segments: Ship, Ocean Development, Machinery, and Engineering. The Ship segment builds commercial ships, naval ships, high speed passenger/vehicle ferries, offshore structures, underwater TV vehicles, steel structures, and ship related equipment; and provides design engineering services. The Ocean Development segment provides floating production storage offloading vessels. The Machinery segment offers marine and stationary diesel engines, marine equipment, gas engines, steam turbines, blowers, process compressors and equipment, gas turbines, cogeneration systems, container cranes, industrial cranes, container terminal management systems, HWM manipulators, wave generators, and induction heaters, as well as equipment of radar sensing for underground and construction. The Engineering segment engages in the power generation and overseas civil/architectural works. The company also engages in the telecommunication equipment related, systems development, gas carriers engineering, and social infrastructure related businesses, as well as operates special facilities for naval ships and aircraft related business. The company was formerly known as Mitsui Engineering & Shipbuilding Co., Ltd. Mitsui E&S Holdings Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Full MIESF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.